The Journal of clinical psychiatry · 2008
Clinical decision making in the treatment of mania.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perlis Roy H
Аннотация
Nine agents are now Food and Drug Administration-approved for acute treatment of bipolar mania, and several other agents are being studied for efficacy. With multiple treatment options available, clinicians face the challenge of selecting among agents. Although clinicians may consult the American Psychiatric Association's Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition, when selecting a treatment for bipolar mania, decisions about many aspects of treatment, such as choosing among agents, comparing combination therapy versus monotherapy, and individualizing treatments, remain complex. Considering data from recent clinical studies that have compared the efficacy, safety, and tolerability of medications for bipolar mania both between and within classes may facilitate such treatment decisions.
Предметные рубрики MeSH
Adverse Drug Reaction Reporting SystemsAntimanic AgentsAntipsychotic AgentsBipolar DisorderDecision Support TechniquesDrug Therapy, CombinationHumansLithium CarbonatePractice Guidelines as TopicRandomized Controlled Trials as TopicTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationValproic Acid